Phase IB/II open-label, randomized evaluation of atezolizumab (atezo) plus selicrelumab (seli) plus gemcitabine plus nab-paclitaxel (gem plus nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC Meeting Abstract
| Authors: | Manji, G.; Bahary, N.; Chung, V.; Dalenc, F.; Ducreux, M.; Gomez-Roca, C.; Im, S. A.; Kortmansky, J.; Lacy, J.; Segal, N.; Tredan, O.; Cirovic, O.; DuPree, K.; Lenain, C.; Lu, D.; Robert, L.; Xu, J.; Zhang, X.; Kim, S. B. |
| Abstract Title: | Phase IB/II open-label, randomized evaluation of atezolizumab (atezo) plus selicrelumab (seli) plus gemcitabine plus nab-paclitaxel (gem plus nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC |
| Meeting Title: | 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 8 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2020 Nov 9-14 |
| Meeting Location: | Virtual |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2020-11-01 |
| Start Page: | A157 |
| End Page: | A158 |
| Language: | English |
| ACCESSION: | WOS:000616665300251 |
| DOI: | 10.1136/jitc-2020-SITC2020.0259 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 259 -- Source: Wos |
